Stock Market Update
23-Apr-26 14:30 ET
S&P 500 slips as healthcare names weigh, West Pharma surges on strong guidance and GLP-1 demand
Dow -214.27
at 49275.76,
Nasdaq -219.91
at 24437.66,
S&P -31.46
at 7106.44
[BRIEFING.COM] The S&P 500 (-0.44%) is in second place on Thursday afternoon, down about 32 points.
Briefly, S&P 500 constituents Bio-Techne (TECH 52.01, -6.57, -11.22%), Revvity (RVTY 84.32, -9.96, -10.56%), and Thermo Fisher (TMO 461.80, -52.18, -10.15%) dot the bottom of the average. TECH and RVTY slip despite a dearth of corporate news, while TMO falls as investors focused on its softer-than-expected Q2 EPS guidance and only modest 3% organic growth outlook, which outweighed the Q1 beat and full-year guidance raise.
Meanwhile, West Pharm (WST 312.43, +38.02, +13.86%) holds firm near the top of the standings after reporting a strong Q1 earnings beat with 15% organic revenue growth driven by high-demand drug components (including GLP-1-related products) and raising full-year EPS and revenue guidance well above consensus, signaling sustained momentum into 2026.
